Leon Samuel Moskatel, MD
Pain Management · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Moskatel’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A159125 · Current
Licensed to practise in California · since 2018 · expires 2026-10-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$32,090
Medicare paid this office $32,090 for 141 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 44 | $9,238 | $159 |
| New patient visit (60+ min) | 49 | $7,642 | $156 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 35 | $6,457 | $95 |
| Long return visit (40+ min) | 25 | $3,932 | $123 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 16 | $1,126 | $45 |
Who their Medicare patients are
141 Original Medicare patients in 2024. Average age 69 · Women 77% · Also on Medicaid 32% · Health risk score 1.11. At or below the middle of the specialty; the typical pain management clinician is at 1.38.
Conditions among them: High blood pressure 60% · Depression 30% · Diabetes 23% · Coronary heart disease 20% · Chronic kidney disease 17% · Stroke 13% · Heart failure 11% · Cancer 11% · Atrial fibrillation 10% · Dementia 8%.
The office billed $191,399, Medicare allowed $43,069 and paid $32,090; for 281 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 141 | 281 | 69 | 1.11 | $191,399 | $32,090 |
| 2023 | 175 | 412 | 70 | 1.22 | $272,699 | $38,553 |
| 2022 | 138 | 197 | 69 | 1.07 | $137,072 | $24,058 |
| 2021 | 30 | 44 | 67 | 0.98 | $32,391 | $5,552 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 90 | $15,111 | $118 |
| New patient visit (60+ min) | 73 | $10,363 | $142 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 40 | $7,597 | $93 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 20 | $3,526 | $65 |
2022: 3 services
| New patient visit (60+ min) | 68 | $10,830 | $159 |
| Long return visit (40+ min) | 57 | $7,650 | $121 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 28 | $4,175 | $102 |
2021: 1 service
| New patient visit (60+ min) | 19 | $3,192 | $168 |
Medicaid work
$64,893 in 2024
Medicaid paid $64,893 for 156 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Botox | 71 | $59,503 |
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 85 | $5,389 |
| 2024 | 156 | 2 | 16 | $64,893 |
| 2023 | 50 | 1 | 14 | $4,071 |
| 2022 | 15 | 1 | 15 | $2,335 |
See the largest Medicaid services in earlier years
2023
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 50 | $4,071 |
2022
| OFFICE/OP CONSLTJ NEW/EST PT HIGH MDM 55 MINUTES | 15 | $2,335 |
Drugs they prescribed that Part D paid
$243,441
Pharmacies billed $243,441 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 509) in 2024. At or below the middle of the specialty; the typical pain management clinician is at 44%.
335 generic and 174 brand-name prescriptions · $243,441 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Emgality | Migraine | 36 | $45,689 | $1,269 |
| Nurtec Odt | None | 21 | $25,635 | $1,221 |
| Ajovy | None | 29 | $25,059 | $864 |
| Ubrelvy | None | 19 | $21,958 | $1,156 |
| Emgality | Migraine | 19 | $20,101 | $1,058 |
See all 17 drugs
| Emgality | Migraine | 36 | $45,689 | $1,269 |
| Nurtec Odt | None | 21 | $25,635 | $1,221 |
| Ajovy | None | 29 | $25,059 | $864 |
| Ubrelvy | None | 19 | $21,958 | $1,156 |
| Emgality | Migraine | 19 | $20,101 | $1,058 |
| Reyvow | None | 17 | $17,624 | $1,037 |
| Eletriptan Hbr | None | 35 | $4,072 | $116 |
| Sumatriptan | None | 12 | $2,094 | $175 |
| Candesartan Cilexetil | None | 18 | $1,633 | $91 |
| Memantine | None | 38 | $731 | $19 |
| Baclofen | None | 12 | $579 | $48 |
| Rizatriptan | None | 29 | $516 | $18 |
| Gabapentin | None | 52 | $452 | $9 |
| Naratriptan | None | 13 | $393 | $30 |
| Oxcarbazepine | None | 11 | $291 | $26 |
| Nortriptyline | None | 16 | $272 | $17 |
| Zonisamide | None | 13 | $98 | $8 |
Year by year
| 2024 | 509 | 95 | 0% (0) | 34% | $243,441 |
| 2023 | 481 | 96 | 0% (0) | 38% | $227,906 |
| 2022 | 183 | 49 | 0% (0) | 25% | $56,431 |
| 2021 | 20 | 12 | 0% (0) | None | $3,503 |
| 2020 | 162 | 13 | 8% (13) | 20% | $11,357 |
| 2019 | 194 | 27 | 9% (17) | 16% | $9,163 |
| 2018 | 16 | None | 0% (0) | None | $279 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Emgality | Migraine | 66 | $78,329 | $1,187 |
| Nurtec Odt | None | 21 | $23,635 | $1,125 |
| Reyvow | None | 24 | $23,459 | $977 |
| Qulipta | None | 15 | $19,968 | $1,331 |
| Ajovy | None | 19 | $18,260 | $961 |
| Aimovig | Migraine | 13 | $10,583 | $814 |
| Memantine | None | 37 | $1,881 | $51 |
| Candesartan Cilexetil | None | 22 | $1,740 | $79 |
| Rizatriptan | None | 47 | $967 | $21 |
| Nortriptyline | None | 14 | $822 | $59 |
| Gabapentin | None | 48 | $629 | $13 |
| Eletriptan Hbr | None | 12 | $617 | $51 |
| Topiramate | None | 19 | $314 | $17 |
2022: 5 drugs
| Emgality | Migraine | 16 | $17,207 | $1,075 |
| Ubrelvy | None | 12 | $11,665 | $972 |
| Memantine | None | 18 | $1,730 | $96 |
| Candesartan Cilexetil | None | 19 | $1,620 | $85 |
| Rizatriptan | None | 17 | $451 | $27 |
2020: 1 drug
| Gabapentin | 18 | $201 | $11 |
2019: 3 drugs
| Gabapentin | 23 | $451 | $20 |
| Lactulose | 11 | $134 | $12 |
| Amitriptyline | 11 | $95 | $9 |
Money from drug and device companies
$32 in 2024
| 2024 | 1 | 1 | None | $32 |
| 2023 | 2 | 2 | None | $163 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Qulipta | $32 | 1 payment
|
See the published payment
| Abbvie | Meals · 2024-11-15 | Qulipta | $32 |
See earlier years (2023)
2023: $163
| Abbvie | Qulipta | $121 | 1 payment
|
| Teva Pharmaceuticals USA | None | $42 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1306377973
- Licence
- CA A159125California A159125: Current · expires 2026-10-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084P2900X (2084P2900X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2017-03-24
- NPI last updated
- 2023-11-07
- NPI record certified
- 2023-11-07
This is when the NPI record was last certified, not a medical board exam.